Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03596476

Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy

Gastro-esophageal reflux disease (GERD) is defined as the reflux of gastric content into the esophagus that causes troublesome symptoms or complications. Nine to 30% of the population suffers from GERD-suggestive symptoms (heartburn, regurgitation, chest pain, chronic couch, sore throat). In the absence of warning signs, proton pump inhibitors (PPI) are prescribed as first-line treatment. However, 20 to 60% of patients are unsatisfied because of persistent symptoms when taking PPI. Causes of persistent symptoms are: erroneous diagnosis of GERD (up to 50% of PPI non-responders), rumination syndrome, excessive weakly acid reflux on PPI due to defective esophago-gastric junction or an excessive number of transient lower esophageal sphincter relaxations (main mechanism of GERD), poor acid secretion inhibition on PPI, and non-compliance to therapy. Complementary examinations are indicated to explain persistent GERD symptoms. Upper gastro-intestinal endoscopy is performed first to rule out an esophageal tumor and to identify erosive esophagitis, a specific sign of GERD. However, it is normal in up to 70% of symptomatic GERD patients. Direct detection of reflux episodes is then requested to confirm GERD. The gold standard for reflux detection is the ambulatory measurement of esophageal pH for 24 to 96 hours using a catheter (catheter-based pH-monitoring) or a capsule clipped into the esophagus (wireless pH-monitoring). Reflux episodes are defined as an esophageal pH < 4. Another method of reflux detection is based on liquid and gas detection in the esophagus using pH-impedance monitoring. Recently the combination of impedance and esophageal pressure monitoring, called esophageal high resolution impedance manometry (HRIM) was introduced to simultaneously identify reflux episodes and their mechanisms. It has several advantages over esophageal pH measurement: shorter recording duration (1 or 2 hours post prandial) and identification of reflux mechanisms that might guide the choice of the best therapeutic option.

Hypothesis: The 1-hour post prandial esophageal HRIM might be useful to diagnose GERD.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Service d'Hepato-Gastroenterologie - Hôpital Trousseau - CHU de Tours, Chambray-lès-Tours, France

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient older than 18 years
  • Typical symptoms of GERD (heartburn, regurgitation) at least twice a week despite PPI therapy for at least one month.
  • Reflux Disease Questionnaire (RDQ) score off PPI > 3
  • Subject with health insurance

Exclusion criteria

  • Previous esophago-gastric surgery,
  • Previous history of developing esophageal or gastric tumor, esophageal stricture, or esophageal varices
  • Pregnancy (assessment at V0)
  • Contraindication to general anesthesia,
  • Contraindications to the wireless capsule pH-monitoring: pacemakers, implantable cardiac defibrillator,
  • Contraindications to HRIM: inability to tolerate nasal intubation, significant bleeding disorders for which nasal intubation is contraindicated, known esophageal obstruction is preventing the passage of the HRIM probe.
  • Intolerance or allergy to one component of the test meal,
  • Intolerance or allergy to PPI,
  • Inability to give consent,
  • Mentally unbalanced patients, under supervision or guardianship
  • Decline to participate in the study,
  • Participation in another study at the same time

Treatment and study plan

Upper gastrointestinal (GI) endoscopy

Procedure

An upper gastrointestinal (GI) endoscopy will be performed at V1. Four esophageal biopsies will be taken in both the proximal and the distal esophagus.

Wireless pH monitoring

Procedure

Wireless pH monitoring will be performed at V1. The pH capsule will be clipped into the esophagus during the upper GI endoscopy. The esophageal pH will be recorded for 96 hours (ambulatory recording).

Post prandial esophageal High Resolution Impedance Manometry

Procedure

Post prandial esophageal HRIM will be performed at V2. The recording will be started after transnasal insertion of the HRIM probe. A standardized meal will be given to the patient (Big Mac, medium portion of French fries, orange juice). The recording will be realized for one hour after the end of the meal.

pH-impedance monitoring

Procedure

24-h pH-impedance monitoring on PPI will be performed at V3. A transnasal catheter will be inserted into the esophagus and the recording will be performed for 24 hours (ambulatory recording).

Primary outcomes

  1. Number of reflux episodes identified on the post prandial HRIM

    Time frame: 1 hour after the end of the meal

    The diagnostic performance of the number of reflux episodes measured by 1-hour post prandial HRIM will be evaluated by estimating the Area Under the ROC Curve and its 95% confidence interval. The gold standard to define GERD will be based on esophageal pH measurements with capsule (GERD is defined as acid exposure time (AET; percentage of total time with esophageal pH < 4) greater than 6% for at least one day on wireless pH monitoring).

Secondary outcomes

  1. Acid exposure time measured on wireless pH-monitoring

    Time frame: 4 days

    The diagnosis of GERD based on pH-monitoring. The diagnosis of GERD is positive if acid exposure time (AET; percentage of total time with esophageal pH < 4) is greater than 6% for at least one day on wireless pH monitoring. The diagnosis of GERD is negative (ie absence of GERD) if the AET is below 4% during the 4 days of wireless monitoring. In the other instance , the diagnosis of GERD is uncertain.

  2. Reflux mechanisms defined on post prandial HRIM

    Time frame: 1 hour after the end of the meal

    Description of the reflux mechanisms associated with reflux episodes: rumination, transient lower esophageal sphincter relaxation (TLESR), defective esophago-gastric junction (EGJ) or unknown.

  3. Baseline impedance measured on post prandial HRIM

    Time frame: 1 hour after the end of the meal

    Measure of baseline impedance on a period without swallow 3 and 5 cm above the proximal border of the esophago-gastric junction

  4. Resting pressure of the esophago-gastric junction

    Time frame: 1 hour

    Measure of the resting pressure of the esophago-gastric junction on a period without swallowing

  5. Esophageal histology

    Time frame: 4 weeks

    Presence of eosinophils cells in the esophageal mucosa > 15/hpf, dilated intercellular spaces, and/or papillar elongation

  6. Response to 4-week regimen of dose PPI

    Time frame: 4 weeks

    Clinical response is defined as a Reflux Disease Questionnaire score on PPI ≤ 3 after 4-week treatment

  7. Normalization of the number of reflux episodes detected on 24-h pH-impedance monitoring performed on PPI

    Time frame: 1 day

    The number of reflux episodes is normalized if the total number of reflux episodes is < 60 /24 h) on pH-impedance monitoring performed on PPI.

  8. Normalization of the acid exposure time measured on 24-h pH-impedance monitoring performed on PPI

    Time frame: 1 day

    The esophageal acid exposure (AET) is normalized if it is below 4% on pH-impedance monitoring performed on PPI.

  9. Patient's preference regarding the type of examination

    Time frame: 1 day

    Percentage of patients who preferred the wireless pH capsule and percentage of patients who preferred HRIM.

Study contacts

Contact information is provided by the study sponsor or research team.

Sabine ROMAN, MD

CONTACT

[email protected]

4 72 11 01 36 ext. +33

Sponsors and collaborators

Lead sponsor

Hospices Civils de Lyon

Other

Registry information

Acronym: PRIMER

Important dates

Study start
2021
Primary completion
2027
Study completion
2027
First posted
Jul 23, 2018
Registry last updated
Jun 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.